Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company focusing on early cancer detection, has announced the addition of Petra Smeltzer Starke as a Brand Ambassador. In this role, Starke will assist in developing and disseminating messaging about the importance of early colorectal cancer detection. The company aims to launch a pivotal PMA trial for its next-generation colorectal cancer screening product by the end of 2025.
CEO Guido Baechler expressed excitement about Starke joining the team, highlighting her extensive experience as invaluable to their mission. Starke, in turn, expressed pride in working with Mainz Biomed as they advance early detection of colorectal cancer and pre-cancerous polyps.
Mainz Biomed N.V. (NASDAQ:MYNZ), un'azienda di diagnostica genetica molecolare focalizzata sulla rilevazione precoce del cancro, ha annunciato l'aggiunta di Petra Smeltzer Starke come Brand Ambassador. In questo ruolo, Starke assisterà nello sviluppo e nella diffusione di messaggi sull'importanza della rilevazione precoce del cancro colorectal. L'azienda punta a lanciare un trial PMA fondamentale per il suo prodotto di screening per il cancro colorectal di nuova generazione entro la fine del 2025.
Il CEO Guido Baechler ha espresso entusiasmo per l'ingresso di Starke nel team, evidenziando la sua vasta esperienza come un valore inestimabile per la loro missione. Starke, a sua volta, ha espresso orgoglio nel collaborare con Mainz Biomed mentre avanzano nella rilevazione precoce del cancro colorectal e dei polipi precoci.
Mainz Biomed N.V. (NASDAQ:MYNZ), una empresa de diagnóstico genético molecular centrada en la detección temprana del cáncer, ha anunciado la incorporación de Petra Smeltzer Starke como Embajadora de Marca. En este rol, Starke ayudará a desarrollar y difundir mensajes sobre la importancia de la detección temprana del cáncer colorrectal. La empresa tiene como objetivo lanzar un ensayo PMA crucial para su producto de detección de cáncer colorrectal de nueva generación antes de finales de 2025.
El CEO Guido Baechler expresó su entusiasmo por la llegada de Starke al equipo, destacando su amplia experiencia como inestimable para su misión. Starke, a su vez, expresó su orgullo por trabajar con Mainz Biomed mientras avanza en la detección temprana del cáncer colorrectal y pólipos precoces.
Mainz Biomed N.V. (NASDAQ:MYNZ), 조기 암 검출에 중점을 둔 분자 유전학 진단 회사는 Petra Smeltzer Starke를 브랜드 홍보대사로 추가했다고 발표했다. 이 역할에서 Starke는 조기 대장암 검출의 중요성에 대한 메시지를 개발하고 배포하는 데 도움을 줄 것이다. 회사는 2025년 말까지 차세대 대장암 선별 검사 제품에 대한 중요한 PMA 시험을 시작할 계획이다.
CEO Guido Baechler는 Starke가 팀에 합류한 것에 대한 기대감을 표현하며, 그녀의 폭넓은 경험이 그들의 사명에 매우 귀중하다고 강조했다. Starke는 Mainz Biomed와 함께 조기 대장암 및 전암성 폴립의 검출을 발전시키는 데 자부심을 느낀다고 전했다.
Mainz Biomed N.V. (NASDAQ:MYNZ), une entreprise de diagnostic génétique moléculaire axée sur la détection précoce du cancer, a annoncé l'ajout de Petra Smeltzer Starke en tant qu'Ambassadrice de Marque. Dans ce rôle, Starke aidera à développer et à diffuser des messages sur l'importance de la détection précoce du cancer colorectal. L'entreprise vise à lancer un essai PMA crucial pour son produit de dépistage du cancer colorectal de nouvelle génération d'ici fin 2025.
Le PDG Guido Baechler a exprimé son enthousiasme quant à l'arrivée de Starke dans l'équipe, soulignant que son expérience étendue était inestimable pour leur mission. Starke, pour sa part, a exprimé sa fierté de travailler avec Mainz Biomed pour faire avancer la détection précoce du cancer colorectal et des polypes précoces.
Mainz Biomed N.V. (NASDAQ:MYNZ), ein Unternehmen für molekulargenetische Diagnostik, das sich auf die frühzeitige Erkennung von Krebs konzentriert, hat die Hinzuziehung von Petra Smeltzer Starke als Markenbotschafterin bekannt gegeben. In dieser Rolle wird Starke helfen, Botschaften über die Bedeutung der frühen Erkennung von Darmkrebs zu entwickeln und zu verbreiten. Das Unternehmen plant, bis Ende 2025 eine entscheidende PMA-Studie für sein Produkt zur Früherkennung von Darmkrebs der nächsten Generation zu starten.
CEO Guido Baechler äußerte sich begeistert über Starkes Eintritt ins Team und hob ihre umfangreiche Erfahrung als wertvoll für ihre Mission hervor. Starke ihrerseits äußerte ihren Stolz auf die Zusammenarbeit mit Mainz Biomed, während sie die frühe Erkennung von Darmkrebs und präkanzerösen Polypen vorantreiben.
- Appointment of Petra Smeltzer Starke as Brand Ambassador to enhance product awareness
- Plans to launch a pivotal PMA trial for next-generation colorectal cancer screening product by end of 2025
- None.
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection
BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer.
“We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the intention to launch a pivotal PMA trial by the end of 2025,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. Petra Smeltzer Starke commented, “I am proud and excited to work with Mainz Biomed as they push the envelope on the early detection of colorectal cancer and importantly the detection of pre-cancerous polyps.”
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Petra Smeltzer Starke
Petra Smeltzer Starke's phenomenal career started from studying international business, trade, and diplomacy at the Prague School of Economics while supporting herself as a model. Petra's passion for Fashion translates into her modeling successes notwithstanding, Starke finished both undergraduate and graduate degrees at the top of her class and moved to the United States to attend law school at Georgetown University.
Starke was first in her class in law school & practiced law at the international law firm of O'Melveny & Myers, LLP representing many political nominees and appointees during the Bush Administration. Starke was subsequently recruited for the Obama Presidential Transition and later the Obama White House where she served as General Counsel to the White House Council of Economic Advisors and Senior Advisor to the President. Starke has Counseled American Presidents, and global Diplomatic Leaders around the world, and established a phenomenal international network. Starke's expertise helped the Biden-Harris Transition Team - ethics and avoiding conflicts of interest.
Petra Smeltzer Starke served on Obama's transition team and later she served as General Counsel to the White House Council of Economic Advisors and Senior Advisor to President Obama.
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
Who is the new Brand Ambassador for Mainz Biomed (NASDAQ:MYNZ)?
What is the main focus of Mainz Biomed's (NASDAQ:MYNZ) product development?
When does Mainz Biomed (NASDAQ:MYNZ) plan to launch its pivotal PMA trial?
What is Petra Smeltzer Starke's role as Brand Ambassador for Mainz Biomed (NASDAQ:MYNZ)?
